SNC116 Therapy for Refractory Systemic Lupus Erythematosus

Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Study ID
NCT07748156
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • SNC116 — DRUG
    The formulation of SNC116 is an injection solution. The initial dose is 2E8 TU and it is administered via a single intravenous infusion.

Study Details

This study aims to evaluate the safety and tolerability of SNC116 in treating patients with systemic lupus erythematosus.

Key Dates

First listed
Aug 5, 2026
Start date
Aug 31, 2026
Status verified
Jul 2026
Primary completion
Jan 31, 2030
Completion
Jan 31, 2030

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SNC116
    intravenous administration

Primary Outcome Measure

Safety Evaluation [ Time Frame: Within 3 months after SNC116 treatment. ]

Central Contacts

Find similar trials

Nationwide
Lupus (SLE) trialsRheumatology trialsAutoimmune disease trials

Related Studies